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AbstrAct
The TRAF-interacting protein (TRAIP) is an E3 ubiquitin ligase required for cell 
proliferation. TRAIP mRNA is downregulated in human keratinocytes after inhibition 
of the PI3K/AKT/mTOR signaling. Since E2F transcription factors are downstream 
of PI3K/AKT/mTOR we investigated whether they regulate TRAIP expression. E2F1 
expression significantly increased the TRAIP mRNA level in HeLa cells. Reporter assays 
with the 1400bp 5’-upstream promoter in HeLa cells and human keratinocytes showed 
that E2F1-, E2F2- and E2F4-induced upregulation of TRAIP expression is mediated by 
168bp upstream of the translation start site. Mutating the E2F binding site within this 
fragment reduced the E2F1- and E2F2-dependent promoter activities and protein-DNA 
complex formation in gel shift assays. Abundance of TRAIP mRNA and protein was 
regulated by the cell cycle with a peak in G2/M. Expression of GFP and TRAIP-GFP 
demonstrated that TRAIP-GFP protein has a lower steady-state concentration than 
GFP despite similar mRNA levels. Cycloheximide inhibition experiments indicated that 
the TRAIP protein has a half-life of around four hours. Therefore, the combination 
of cell cycle-dependent transcription of the TRAIP gene by E2F and rapid protein 
degradation leads to cell cycle-dependent expression with a maximum in G2/M. These 
findings suggest that TRAIP has important functions in mitosis and tumorigenesis. 
IntroductIon
The TRAF-interacting protein (TRAIP, TRIP, 
RNF206) is a 53-kDa protein that contains at its 
N-terminal end a 55 amino acids long RING domain, 
followed by a putative coiled-coil domain and a leucine 
zipper region [1]. TRAIP undergoes auto-ubiquitination in-
vitro and, by this criterion, can be considered as functional 
E3 ubiquitin ligase of the RING class [2]. Historically, 
TRAIP was reported to interact with the tumor necrosis 
factor (TNF) receptor-associated factors (TRAFs) [2, 3]. 
Ectopic expression of TRAIP repressed NF-κB signaling 
in a RING domain independent manner [2, 3], however, 
this is most likely a non-physiological function [1]. TRAIP 
is expressed at low levels in most tissues [3, 4] where it is 
mainly found in the nucleolus of interphase mammalian 
cells [5]. The nucleolus is a major nuclear substructure 
with prominent functions in ribosome formation, the 
control of the cell cycle and stress responses [6].
TRAIP is required for early mice development 
since homozygous TRAIP knock-out mice die at 
embryonic day E6.5/7.5 caused by decreased number 
of proliferative cells and excessive apoptosis [7]. In a 
screen for cell cycle regulators, Drosophila maternal 
effect-lethal mutants affecting the ‘no poles’ (NOPO) 
gene (CG5140) were identified [8]. This gene encodes a 
protein with a N-terminal domain showing 47% sequence 
identity with the RING domain of human TRAIP [8]. The 
RING domain of one of the NOPO mutants contained a 
lysine instead of a glutamic acid at position 11, affecting 
an amino acid highly conserved in TRAIP homologues. 
Embryos expressing mutant NOPO undergo mitotic arrest 
during early embryogenesis showing acentrosomal mitotic 
spindles as most prominent feature [8]. 
Recently, it has been reported that NOPO/
TRAIP interacts with DNA polymerase η which 
facilitates translesional synthesis after DNA damage 
[9]. Furthermore, TRAIP is a regulator of the spindle 
assembly checkpoint (SAC) by regulating MAD2 levels 
at kinetochores [10]. In addition, TRAIP interacts with 
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CYLD [11] and Syk [5], two tumor suppressors implicated 
in the formation of skin appendages tumors such as 
cylindroma, trichoepithelioma and spiradenoma (CYLD) 
[12, 13] and of melanomas and breast tumors (CYLD and 
Syk) [14-18]. 
The TRAIP mRNA level is strongly decreased 
in primary human epidermal keratinocytes (NHEK) 
undergoing differentiation induced by high calcium 
concentration, high cell density or phorbol ester [19], 
indicating that TRAIP expression is down-regulated 
when cells exit the cell cycle and undergo differentiation. 
Inhibition of PI3K or mTOR in proliferating keratinocytes 
reduced also TRAIP mRNA expression [19]. Knock-
down of TRAIP by lentiviral-transduced shRNA in 
primary keratinocytes resulted in strong inhibition of 
cell proliferation and a G1/S cell-cycle arrest [19]. These 
results indicated that TRAIP is implicated in the regulation 
of cellular proliferation and/or survival.
E2F transcription factors are involved in many 
ways in the regulation of genes for proliferation, DNA 
replication, apoptosis and differentiation [20]. E2F DNA-
binding sites have been found in the promoters of many 
genes that are crucial to direct cell cycle progression. 
Eight proteins (E2F1-E2F8) belong to this family of 
transcription factors which are subdivided into activators 
(E2F1-E2F3a), repressor (E2F3b-E2F5) and inhibitors 
(E2F6-E2F8) [21]. The transcriptional activity of E2F1-
E2F5 is regulated by the retinoblastoma protein (pRb) or 
the related pocket proteins p107 and p130 [22]. To attain 
their full transcriptional activity and to bind DNA with 
high affinity, E2F1-E2F6 are required to heterodimerize 
with dimerization partner (DP) proteins [23].
In this report we show that TRAIP gene expression 
is induced by E2F1, E2F2 and E2F4 through an E2F 
binding site located in the 5’upstream promoter region 
close to the transcription start site. TRAIP mRNA and 
protein expression correlated with a peak in the G2/M 
phase suggesting that TRAIP has physiological function(s) 
in G2/M.
results
e2F1-dependent upregulation of trAIP 
expression is inhibited by the retinoblastoma 
protein
Previously, we have shown that inhibitors targeting 
PI3-Kinase (LY294002) or mTOR (rapamycin) decreased 
TRAIP gene expression in proliferating keratinocytes [19]. 
These findings strongly suggested that TRAIP expression 
was regulated by the PI3K/Akt/mTOR signaling pathway. 
Since the E2F transcription factors are well known targets 
Fig.1: trAIP mrnA expression is induced by e2F1 but repressed by rb. Relative mRNA levels of TRAIP (A and C) and 
CCNE1 (B and D) were measured in HeLa cells 24 (black bars) and 48 (white bars) hours after transfection with the indicated plasmids. 
In the experiments C and D cells were transfected with 400ng pCMV6E2F1 and 600ng pCMV6RB1 plasmid. Control denotes cells 
transfected with an empty expression vector. RPL13A was used for normalization in quantitative PCR analysis. Results (mean±SD) were 
derived from 4 independent experiments. Statistical significance of differences between sample and control values was calculated by two-
sided paired t-tests, * p<0.05.
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of this pathway [24 , 25] and, in addition, rapamycin 
modulates directly or indirectly the transcriptional activity 
of E2F [24, 26-28], we sought to determine whether 
TRAIP is a transcriptional target of E2Fs by transfecting 
HeLa cells with the vector pCMV6E2F1 expressing E2F1 
or an empty control vector. After transfection, cells were 
cultured in low-serum medium (0.25% fetal bovine serum) 
in order to reduce endogenous E2F activity and to exclude 
that serum factors affected the results. RNA was isolated 
24 and 48 hours posttransfection and the expression 
of TRAIP and cyclin E1 (CCNE1) was determined by 
quantitative RT-PCR analysis. The results demonstrated 
that TRAIP expression was significantly increased by 
E2F1 in a dose-dependent manner at 24 and 48 hours 
posttransfection compared to control cells (Fig. 1A). The 
transcriptional synthesis of CCNE1, a well-known E2F1 
target gene [29, 30], was massively upregulated (Fig. 1B), 
demonstrating the validity of the experimental system 
used to detect E2F1 targets in HeLa cells. 
Previously, it has been shown that the hypo-
phosphorylated form of the retinoblastoma (pRB1) 
protein binds to E2F1 leading to the inhibition of its 
transcriptional activity [31, 32]. To determine whether 
the E2F1-dependent activation of TRAIP expression is 
suppressed by pRB1, HeLa cells were co-transfected with 
E2F1 and pRB1, and 24 hours post-transfection RNA 
was isolated for RT-qPCR analysis. The results showed 
that pRB1 repressed the E2F1-mediated upregulation of 
TRAIP mRNA expression (Fig. 1C), similarly to the effect 
of pRB1 on CCNE1 expression (Fig. 1D). In summary, 
these experiments demonstrated that the expression of the 
TRAIP gene is antagonistically regulated by E2F1 and 
pRB1.
In silico analysis of the 5’-upstream trAIP 
promoter
In silico analysis of the 1.4kbp 5’-upstream region 
of the human and mouse TRAIP gene detected two 
conserved regions with similarity to the consensus E2F 
binding sequence [33]. In the human gene, one of these 
binding sites is located downstream of the putative TRAIP 
transcription start site at the position +16 to +25 whereas 
the second one is found upstream of the transcription 
start site at position -628 to -621 (Fig. 2). We therefore 
investigated whether these two E2F binding sites are 
involved in the control of TRAIP expression by E2F 
transcription factors. 
Identification of a functional E2F site in the 
proximal promoter
Reporter constructs driven by different deletion 
fragments A-F (Fig. 2) from the 1.4kbp TRAIP 
5’-upstream promoter (-1455/+117; positions +1 and +117 
denote the transcription start site and the G residue of the 
start codon, respectively; data according to ENSEMBL 
ENSG00000183763) were prepared by cloning into the 
pGL3-Basic vector. HeLa cells were co-transfected with 
the different reporter constructs and plasmids expressing 
E2F family members (E2F1, E2F2, or E2F4). The 
plasmids pcDNA3 and pGL3-Basic were used as control 
for expression and reporter constructs, respectively. 
Firefly luciferase activities were adjusted for transfection 
efficiency with the co-transfected Renilla luciferase 
activity. The E2F1-, E2F2-, and E2F4-dependent 
reporter activities with the promoter fragments A-E were 
comparable and significantly higher than with the pGL3-
Basic vector (Fig. 3A-3C). In contrast, the reporter activity 
Fig.2: schematic overview of the 5’ promoter region of the human trAIP gene. The two putative E2F binding sites with 
their positions relative to the transcription start site are indicated by arrows. The 6 deletion constructs (A-F) which were cloned into the 
pGL3-Basic luciferase reporter vector are shown below. The transcriptional initiation site is designated as +1 and the nucleotide A of the 
translation start codon as +115.
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of fragment F containing the whole promoter with the 
exception of 152 bp upstream of the translation initiation 
codon was indistinguishable from the pGL3-Basic vector 
with all 3 transcription factors (Fig. 3A-C). These findings 
argued that the 168 bp region upstream of the translation 
initiation codon, corresponding to construct E (Fig. 2), 
contained the functional E2F binding site responsible for 
E2F1-, E2F2- and E2F4-dependent transactivation of the 
upstream promoter of the human TRAIP gene in HeLa 
cells. 
Next, we tested the E2F1-dependent reporter 
activities of the different promoter fragments in primary 
human keratinocytes (NHEK) cultured in low-calcium 
medium. The results demonstrated that the fragments 
A-D had very similar reporter activities which were 
significantly higher than the basic vector whereas the 
activity with fragment F was not increased (Fig. 3D). 
Taken together, we found that only the 168 bp region 
(-51/+117, Fig. 2) upstream of the translation initiation 
codon was required for the E2F-induced TRAIP gene 
expression in different cells. This is in good agreement 
with the in silico identified conserved E2F transcription 
factor binding site located at position +16 to +25 (Fig. 2). 
The second putative E2F binding site (-628/-621, Fig. 2) 
does not seem to be involved in E2F-dependent regulation 
of TRAIP.
Previously, we have reported that addition of TPA 
to NHEK cultured in low calcium medium repressed 
TRAIP expression within 24 hours [19]. Therefore, 
we investigated whether the promoter activity from the 
5’upstream region of the TRAIP gene was modulated 
by TPA. NHEK were cultured in low calcium medium, 
transfected with reporter constructs and subsequently 
treated with 1µM TPA for 24 hours before measuring 
luciferase activities. The results demonstrated that the 
reporter activities of the promoter fragments A to D were 
significantly reduced upon TPA treatment compared to 
the control vector (Fig. 3E). In contrast, the activity from 
Fig.3: A functional e2F binding site in the trAIP promoter is located close to the transcription start site. Fold induction 
of reporter activity in HeLa (A-C) cells or NHEK (D-E) transfected with 750ng pCMV6E2F1 (A, D), pCMV6E2F2 (B), pCMVE2F4 (C), 
or treated with 1µM TPA (E) after transfection of reporter plasmids. Results are expressed as mean±SD from 3-8 experiments performed 
in duplicates. Statistical significance of differences of reporter activities between promoter plasmids versus pGL3-Basic was calculated by 
two-sided t-tests, * p<0.05.
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fragment F was rather increased, albeit not significantly, 
by TPA. These findings implied that TPA regulated the 
transcriptional activity of the 5’-upstream part of the 
TRAIP promoter in a negative manner and localized the 
TPA-responsive region to the proximal 168 bp fragment 
of the promoter, similarly as shown above for the E2F-
response element.
To further prove the binding of E2F transcription 
factors to the E2F site at +16 to +25 (Fig. 2), the site was 
mutated from 5’-TTTGGCTC-3’ to 5’-TTTATCTC-3’ in 
the full-length promoter (fragment A, Fig. 2). The mutation 
of the proximal E2F binding site significantly reduced 
the E2F1- and E2F2-dependent luciferase activities in 
comparison to the wild type promoter in HeLa cells (Fig. 
4A). In electrophoretic mobility shift assays (EMSA) 
using biotinylated oligonucleotides spanning the proximal 
E2F binding site (WT) a slower moving protein-DNA 
complex appeared after incubation with nuclear extracts 
from proliferating HeLa cells (Fig. 4B, lane 2), which 
was strongly reduced by competition with 200-fold molar 
excess of non-biotinylated WT oligonucleotides (Fig. 
4B, lane 3). No complex was formed after incubation of 
HeLa nuclear extracts with biotinylated oligonucleotides 
containing mutations in the E2F binding site (Mut) (Fig. 
4B, lane 4). Furthermore, a 200-fold molar excess of non-
biotinylated Mut oligonucleotides was unable to compete 
with the biotinylated WT oligonucleotides (Fig. 4B, lane 
5). In summary, these data strongly suggest the TRAIP 
expression is regulated by E2F transcription factors 
through a functional binding site localized in the proximal 
region of its 5’upstream promoter.
endogenous trAIP expression is cell cycle 
regulated with a peak in mitosis
Since the TRAIP gene is a target of the cell 
cycle-dependent transcriptional activity of E2Fs we 
addressed the question whether endogenous TRAIP gene 
expression is modulated by the cell cycle. HeLa cells were 
synchronized either in the G0/G1, S or G2/M phase by 
serum starvation, double thymidine block or nocodazole 
treatment, respectively. Analysis of the cell cycle 
distributions by fluorescence-activated flow cytometry 
Fig.4: Mutational inactivation of the proximal e2F binding site reduces reporter and eMsA activity. (A) Reporter activity 
of the normal (WT) and the mutated (Mut) TRAIP promoter with E2F1 (left) and E2F2 (right). Results are expressed as mean±SEM from 
5 experiments performed in duplicates. Statistical significance of differences of reporter activities between WT and Mut was calculated by 
two-sided t-tests, ** p<0.01. (B) EMSA experiments with normal (WT) and E2F-mutated (Mut) oligonucleotides using HeLa cell nuclear 
extracts. Comp; competition with 200-fold molar excess of oligonucleotide added before the biotinylated (biotin) oligonucleotide. Arrow, 
free oligonucleotide; arrow head, protein-DNA complex.
Oncotarget20938www.impactjournals.com/oncotarget
analysis of propidium iodide stained cells revealed that 
a high percentage of cells was arrested in the desired cell 
cycle phase: G0/G1, 62.8 ± 2.2%; S, 72.6 ± 5.3%; G2/M, 
80.3 ± 3.0%; mean ± SEM, n=4. Endogenous TRAIP 
mRNA levels in the three cell cycle phases were measured 
by quantitative RT-PCR analysis using four house-
keeping genes (RPL13A, GAPDH, RPL3 and B2M) for 
normalization. Previous experiments reported that their 
gene expression levels are minimally regulated during the 
cell cycle [34]. The results showed that the expression of 
the TRAIP mRNA was significantly higher in G2/M phase 
cells compared to G0/G1 phase cells with all genes used 
for normalization (Fig. 5A-D). The expression of TRAIP 
in the G2/M phase was also significantly higher than in S 
phase after normalization with 3 out of 4 house-keeping 
genes (RPL13A, RPL3 and B2M). To verify whether the 
experiment was able to predict correctly the cell cycle-
dependent expression peak of other genes [34], the mRNA 
levels of E2F1, CCNE1, and CCNB1 were measured in 
the same synchronized cell populations. As expected, 
significantly elevated levels of E2F1, CCNE1, and CCNB1 
expression were found in the G0/G1, S, and G2/M phase 
(Fig. 5A-D), respectively, validating our TRAIP data. To 
further corroborate these data, HeLa cells were blocked 
in mitosis by nocodazole treatment, then released into 
normal medium and protein extracts were prepared every 
three hours. Quantitative Western blot analysis using actin 
for normalization of protein loading revealed that TRAIP 
Fig.5: trAIP is predominantly expressed in the G2/M phase of the cell cycle. RNA was extracted from HeLa cells synchronized 
in the G0/G1, S and G2/M phase as described in Materials and Methods. Relative gene expressions for E2F1, CCNE1, CCNB1 and TRAIP 
were normalized either with RPL13A (A), GAPDH (B), RPL3 (C) and B2M (D) by quantitative RT-PCR. Results are depicted as scatter 
plots of 2-∆ Ct values (mean±SD, 4 independent experiments). Statistical significance of the differences of the 2-∆Ct values between the cell 
cycle phases was calculated by two-sided t-tests; * p<0.05. (E) Western blot analysis of TRAIP and cyclin B1 expression as function of time 
after release of nocodazole-blocked HeLa cells into normal medium. (F) Protein quantification of cyclin B1 (white bars) and TRAIP (black 
bars) expression after release from nocodazole block. Results are shown as mean±SD from two experiments using normalization with actin. 
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protein expression was cell cycle regulated with a peak 
at 15 to 18 hours after the release into nocodazole-free 
medium (Fig. 5E-F). Again, the expression of the G2/M 
marker cyclin B1 in the same cell extracts followed a 
kinetic similar to TRAIP protein levels. Thus, the data 
indicated that TRAIP gene and protein expression are cell 
cycle regulated with a maximum in the G2/M phase.
trAIP protein has a short half-life
To investigate whether TRAIP protein expression 
was regulated post-transcriptionally, vectors driving 
expression of TRAIP-GFP and GFP from a CMV 
promoter were constructed. TRAIP-GFP was undergoing 
auto-ubiquitination [2] and localized correctly to the 
nucleolus [5] as the endogenous protein, indicating that 
adding GFP at the C-terminal end of TRAIP did not 
adversely affect the enzymatic activity or the subcellular 
localization of the fusion protein [10]. HeLa cell lines 
stably expressing TRAIP-GFP or GFP were obtained 
by lentiviral infection at equal MOI and hygromycin 
selection for 11 days. Immunoblot analysis with anti-
GFP-antibody revealed that the protein level of TRAIP-
GFP was significantly reduced compared to GFP although 
their steady-state mRNA levels measured by RT-qPCR 
using GFP-specific primers were very similar (Fig. 5A). 
This finding suggested that the TRAIP protein level 
was post-transcriptionally down-regulated, either due 
to reduced efficiency of mRNA translation or a higher 
protein degradation rate. To examine this, 293T cells were 
transiently co-transfected with expression vectors for 
TRAIP-FLAG and GFP and the decrease of TRAIP-FLAG 
in the first 6 hours of cycloheximide (50µg/ml) treatment 
was assessed by immunoblots. GFP or actin were used 
for normalization since their expressions are more or less 
stable during the 6 hours of cycloheximide treatment, 
considering their reported half-lives (26 hours for GFP 
[35], 48 hours for actin [36, 37]). A representative example 
of the exponential decay of TRAIP-FLAG is shown in Fig. 
5B. The calculation [38] from 4 independent experiments 
revealed a TRAIP half-life (mean±SD) of 4±1.4 hours 
or 3.7±1.6 hours using normalization with either GFP or 
actin, respectively. These findings indicated that TRAIP is 
an unstable protein explaining the different protein steady-
state levels of TRAIP-GFP and GFP in stable HeLa cell 
lines described above.
dIscussIon
Cell cycle progression is a complex physiological 
process coordinated by a multitude of signaling 
pathways that are regulated by internal and external cues. 
Experiments using shRNAs, knockout mice and inhibitors 
showed that the E3 ubiquitin ligase TRAIP is necessary 
for cellular proliferation [7, 19]. Since TRAIP expression 
is regulated by the PI3K/AKT/mTOR pathway [19], 
which acts upstream of E2F [25-27], we hypothesized 
that TRAIP is an E2F target gene. Ectopic expression 
experiments in HeLa showed that TRAIP gene expression 
is antagonistically regulated by E2F1 and pRB1 (Fig. 1). 
Indeed, in silico analysis of the 5’ upstream region of 
Fig.6: trAIP protein has a short half-life. (A) Immunoblot with anti-GFP antibody (upper panel) and GFP-specific qRT-PCR 
(lower panel) analysis in HeLa cells infected at identical MOI with lentivirus expressing GFP or TRAIP-GFP at 11 days post-transduction. 
Actin served as loading control in immunoblot and the GFP mRNA level was normalized with RPL13A. (B) Decay of TRAIP-FLAG 
protein after addition of cycloheximide (50ug/ml) at time 0. TRAIP quantity was normalized with actin. One representative example from 
several similar experiments is shown.
Oncotarget20940www.impactjournals.com/oncotarget
the human and mouse TRAIP genes revealed two highly 
conserved putative E2F sites (Fig. 2). Luciferase reporter 
analysis of the human TRAIP promoter indicated that 
most, if not all, of the E2F1-, E2F2-, and E2F4-dependent 
transactivation occurred through the E2F site immediately 
adjacent to the transcriptional start site (Fig. 3A-E), 
consistent with the observation that many functional 
E2F binding sites are located close to the transcription 
start site [39]. The results from the promoter analysis 
were not dependent on whether HeLa cells or human 
keratinocytes were used, indicating that most likely the 
proximal E2F binding site is important for E2F-dependent 
TRAIP expression in most tissues. E2F4 was found to 
activate the TRAIP promoter (Fig. 3C) which might be 
surprising since this E2F transcription factor is normally 
thought to function as repressor. However, recent studies 
indicated that E2F4 can act both as activator and repressor 
depending on the cellular context and the target gene 
[40]. The TPA-mediated TRAIP repression in human 
keratinocytes [19] (Fig. 3E) required only the 168bp 
fragment containing the proximal E2F site (fragment E, 
Fig. 2), which would be consistent with data that TPA-
mediated activation of PKC inhibits AKT, thus decreasing 
E2F activity, in mouse keratinocytes [41]. The sequence 
of the proximal E2F binding site (TTTGGCTC) resembles 
closely the E2F consensus sequence (TTT G/C G/C 
CGC) [42]. The functional relevance of the proximal E2F 
binding site in the upregulation of TRAIP expression was 
further underlined by comparing wild type and mutated 
E2F site in reporter assays using the full-length promoter 
(fragment A) and gel shift experiments (Fig. 4). Inspection 
of large databases from ChIP-on-chip and ChIP-seq 
experiments, such as ChIPBase [43] and ENCODE 
(encodeproject.org), and published data [33, 40, 44-46] 
provided consistent evidence for the binding of E2Fs to 
the promoter of the human TRAIP gene in close proximity 
to the transcription start site using different cell lines 
and experimental conditions. For example, the repressor 
complexes E2F4/p130 [44] and E2F4/Sin3a/Sin3b [45] 
were found to bind to the 5’ upstream TRAIP promoter 
using ChIP-on-chip analysis in cell cycle-arrested cells 
and mouse muscle cells undergoing gene silencing 
during myogenic differentiation. These findings clearly 
established that TRAIP gene is a novel direct target of 
E2F1, E2F2 and E2F4. The transactivation occurs through 
the proximal promoter region containing a bona fide E2F 
binding site close to the transcription start site. The finding 
that several E2F transcription factors modulate TRAIP 
expression in a comparable manner is not surprising since 
these transcription factors may have redundant regulatory 
roles in normal and tumor cells [46]. 
The distal E2F site (TTGGAGG) at the position 
-628/-621 (Fig. 2) does not seem to play any role in TRAIP 
promoter activity under the conditions we have tested. 
Since the similarity to the consensus sequence is lower 
compared to the proximal site, E2Fs may bind only with 
low affinity. However, under other conditions the binding 
site might still be functional, possibly in connection with 
other transcription factors and co-regulators, since not all 
functional E2F binding sites match closely the consensus 
sequence [33].
Deregulation of E2F activity, through 
overexpression or gene amplification [47-49], or loss of 
pRB1, through viral proteins or mutations, are frequent 
events causing different types of human tumors. Since 
TRAIP gene expression is under control of E2F/pRB1, an 
increase in E2F transactivation or pRB1 inactivation in 
tumors could augment the TRAIP level. Mice in which 
all 3 members of the retinoblastoma family (RB1, p107 
and p130) were ablated in liver tissue showed increased 
Traip expression in hepatocellular carcinoma compared 
to normal tissue [50]. Analysis of gene expression in 
tamoxifen-treated RbF/F; K14CreERTM; E2F1-/- mouse 
skin showed a strong decrease in Traip mRNA compared 
to normal skin [51]. Thus, these in vivo results fit well 
with our in vitro data showing antagonistically regulation 
of TRAIP by E2F1 and RB1. Recent work showed 
that TRAIP expression is increased in breast epithelial 
cell lines [5], in breast tumors [52], and in basal cell 
carcinomas (BCC) [19] with a concomitant decrease in 
CYLD expression [16, 53], a tumor suppressor interacting 
with TRAIP [11]. It has been demonstrated in different 
cultured mammalian cells and Drosophila that activation 
of the Hedgehog pathway, a hallmark of BCCs [54], leads 
to the upregulation of cyclins and E2F transcription factors 
[55-58]. Hence, this most likely provides an explanation 
for the overexpression of TRAIP in BCCs. Interestingly, 
CYLD delays G1-S transition by suppressing cyclin D1 
expression and E2F activity [59, 60], and influences 
mitosis [61]. How TRAIP and CYLD functionally interact 
in cell cycle regulation and cancer development remains 
to be explored. 
The expression of E2F transcription factors and 
their target genes are modulated during the cell cycle. 
E2F transcription factors not only play an important 
role in controlling genes in G1/S phase to coordinate 
DNA replication, but also regulate genes in G2/M phase 
encoding proteins important for mitosis [20]. Consistently, 
TRAIP mRNA and protein expression levels are regulated 
during the cell cycle reaching a maximum in the G2/M 
phase (Fig. 5). This is supported by a genome-wide study 
of gene expression as function of the cell cycle in HeLa 
cells which listed TRAIP as a periodically expressed gene 
with a maximum in G2/M [34]. Since the steady-state 
amount of mRNAs is the combined outcome of synthesis 
and degradation, the decline in mRNA level after mitosis 
exit indicates that degradation may be important for 
TRAIP mRNA regulation during the cell cycle. In silico 
analysis of 3’-UTR of TRAIP mRNA did not reveal any 
AU-rich elements which are often, but not always, linked 
to rapid mRNA turnover [62, 63]. Recently, microRNA 
emerged as important factor regulating mRNA half-life 
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[64]. Indeed, bioinformatic analysis of TRAIP mRNA 
detected several evolutionary conserved microRNA 
binding sites in its 3-’UTR. A Traip mRNA half-life of 
approximately 3.3 hours was found in mouse embryonic 
stem cells using different culture conditions [65] indicating 
that the Traip mRNA has an intermediate stability. TRAIP 
protein abundance followed closely mRNA expression 
with a peak in G2/M suggesting a strong correlation 
between mRNA and protein synthesis and degradation. 
Cycloheximide inhibition experiments demonstrated that 
TRAIP is a short-lived protein with a half-life around 4 
hours although stability analysis using the N-terminal rule 
[66, 67] predicts that it should be a stable protein with 
a half-life greater than 20 hours (ProtLifePred, http://
protein-n-end-rule.leadhoster.com/). In addition, no good 
PEST [68] motives (epestfind program in the EMBOSS 
package, http://emboss.sourceforge.net/) were detected in 
the TRAIP amino acid sequence.
The two findings that the TRAIP protein is unstable 
and expressed in a cell cycle-dependent manner as E2F 
target gene with a peak in the G2/M phase, confer upon 
TRAIP two properties commonly found for proteins 
involved in mitosis or cell cycle regulation [69]. During 
mitosis, numerous molecular factors check for correct 
mitotic spindle formation and sister chromatid separation 
to guarantee equal distribution of the genetic material to 
daughter cells [70]. Interestingly, mitotic defects during 
syncytial divisions in Drosophila melanogaster embryos 
harboring RING domain mutants in the NOPO gene, the 
insect homolog of TRAIP, have been reported [8]. This 
is consistent with our recent results showing that knock-
down of TRAIP in HeLa cells reduced MAD2 recruitment 
to kinetochores and consequently strongly compromised 
the activity of the spindle assembly checkpoint, ultimately 
leading to chromosome alignment and segregation defects 
[10]. Together with the results reported herein, the 
conclusion emerges that the TRAIP quantity is tightly 
regulated at the transcriptional and the posttranslational 
level to provide high amounts of TRAIP at a specific point 
during the cell cycle (G2/M) where it is physiologically 
required to ensure the mitotic progression of cells with 
faithful distribution of chromosomes to daughter cells. 
In summary, we report novel biological properties of 
TRAIP which is an E3 ubiquitin ligase essential for cellular 
proliferation. We show that the cellular TRAIP level is 
tightly regulated by E2F-mediated transactivation and 
rapid protein turnover to precisely deliver high amounts 
of TRAIP in the G2/M phase, which is correlating well 
with its reported functions during mitosis. To understand 
fully the biological functions of TRAIP, the identification 
of its physiological substrates will be necessary. Since 
overexpression of TRAIP has been reported in basal cell 
carcinomas [19], breast cancer [5, 52] and melanomas 
(unpublished results), targeting TRAIP or its substrates 
may provide new possibilities for therapeutic interventions 
in tumors. 
MAterIAls And Methods
cell culture
HeLa, 293T, and 293FT cells were cultured in 3T3 
medium [19]. NHEK from foreskin were cultured until 
passage 5 as described [19].
Plasmid constructions
Full-length human TRAIP cDNA was isolated from 
human keratinocytes by RT-PCR and inserted into the 
pGEM-T-Easy vector (Promega). All vectors used for the 
expression of TRAIP and GFP proteins were constructed 
by PCR amplification and cloning either into pEGFP-N3 
(Clontech), pCI (Promega) or pCDH-CMV-MCS-EF1-
Hygro (BioCat). Promoter fragments from the 5’-upstream 
region of the human TRAIP gene were isolated by PCR 
and cloned into the pGL3-Basic vector (Promega). 
Mutations in the E2F binding site were introduced by 
overlapping PCR amplification using Platinum Pfx 
DNA Polymerase (Invitrogen) and primers containing 
the desired mutations. All constructs were verified by 
sequence analysis. Expression plasmids were purchased 
from Open Biosystems (E2F1; E2F4; and pRB1) or 
Addgene (E2F2, Addgene plasmid 24226).
lentiviral production, titration, and infection
Lentiviral particles were produced in 293FT cells 
using the packaging vectors pMD2.G (Addgene plasmid 
12259) and psPAX2 (Addgene plasmid 12260), and 
titrated as described previously [19]. HeLa cells were 
infected with lentiviral supernatant in the presence of 6 
µg/ml Polybrene (Millipore) at a multiplicity of infection 
of 10. Twenty-four hours later, cells were selected for 5 
to 7 days with 800µg/ml hygromycin (Calbiochem) until 
mock-transduced cells were dead.
cell cycle synchronization in hela cells
HeLa cells were synchronized in G0 phase by 3 days 
of serum starvation, in S phase by double thymidine block 
(15h in medium supplemented with 2mM thymidine, 10h 
release, 15h with 2mM thymidine), and in M phase by 15h 
treatment with 400ng/ml nocodazole. Synchronized cells 
were stained with propidium iodide and analyzed for cell 
cycle distribution by flow cytometry as described [19].
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rnA isolation, synthesis of cdnA and qrt-Pcr
RNA was extracted from cultured cells using the 
RNeasy Mini Kit (Qiagen) and cDNA was produced using 
the Primescript RT reagent kit (TakaRa). Quantitative PCR 
analysis was performed with Power SYBRGreen PCR 
Mastermix (Applied Biosystems) using Quantitect Primer 
Assay (Qiagen) primers. Relative gene expression was 
calculated as described [71].
luciferase reporter assay
HeLa cells or normal human epidermal 
keratinocytes (NHEK) were seeded in 24-well plates (2-
3x104 cells per well) in 3T3 medium or EpiLife medium 
with growth supplements, respectively [19]. Cells were 
transfected the following day with 250ng of the promoter-
containing plasmids and 750ng of plasmids encoding 
transcription factors using jetPRIME (PolyPlus; for HeLa 
cells) or jetPEI (PolyPlus; for NHEK) as recommended. 
Cells were co-transfected with 20ng pTK-RL expressing 
Renilla luciferase to control for transfection efficiency. 
After transfection, HeLa cells were cultured in low-serum 
medium (0.25% (v/v) fetal bovine serum) and NHEK in 
EpiLife medium with growth supplements. Luciferase 
activities were measured 24 hours later using the Dual 
Luciferase Assay Kit (Promega). Reporter activity 
was calculated by dividing the firefly with the Renilla 
luciferase activity. The ratio of reporter activities for 
the different promoter constructs was normalized to the 
pGL3-Basic vector, arbitrarily set to 1 (results expressed 
as fold induction). 
nuclear extracts and electrophoretic mobility 
shift assay
Nuclear extracts from HeLa cells were prepared 
using the Nuclear and Cytoplasmic Extraction Kit 
(ThermoScientific). Electrophoretic mobility shift assays 
were carried out using the LightShift chemiluminescence 
EMSA kit (ThermoScientific) following the 
manufacturer’s protocol. The following 5’-biotinylated 
double-stranded oligonucleotides were used as probes: 
WT, 5’-CCCGCTCCAGGAAGTCGTGCTGCGGAGC 
CAAATTTG-3’ (the E2F binding site is underlined) and 
Mut, 5’-CCCGCTCCAGGAAGTCGTGCTGCGAT 
CATGCGTTTG-3’ (the mutated E2F binding site is 
underlined). The same oligonucleotides without the 
biotin were used at 200-fold molar excess for competition 
experiments. After incubation, the reaction products were 
resolved on a 5% polyacrylamide gel in 0.5xTBE and 
transferred to HyBond N+ membrane (Amersham).
Protein extractions and Western blot analysis
Proteins were extracted from cells by lysis in 1% 
SDS/phosphate-buffered saline. The following antibodies 
were used for immunoblots: GFP (Clontech), actin 
(Sigma), FLAG (Sigma), and cyclin B1 (Cell Signaling 
Technology). Signals from immunoblots were captured by 
LAS4000 and quantified by ImageJ.
statistical analysis 
Statistical analysis was performed with GraphPad 
Prism 6 and results with p<0.05 were considered 
significant.
In silico promoter analysis
The 5’upstream region of the human and mouse 
TRAIP genes were analysed by the rVISTA 2.0 program 
to find transcription factor binding sites that are 
phylogenetically conserved [72]. 
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